RTS,S/AS02A for malaria

References

• Rogan WJ, Chen A. Health risks and benefits of bis (4-chlorophenyl)- 1,1,1-trichloroethane (DDT). Lancet366, 763–773 (2005).
   PubMed Web of Science ®Google Scholar
• Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst. Rev.2, CD000363 (2000).
   Google Scholar
• Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet365, 1487–1498 (2005).
   PubMed Web of Science ®Google Scholar
• Sachs J, Malaney P. The economic and social burden of malaria. Nature415, 680–685 (2002).
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Goh LM, Luke TC et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis.185, 1155–1164 (2002).
   PubMed Web of Science ®Google Scholar
• Webster D, Hill A. Progress with new malaria vaccines. Bull. World Health Organ.81, 902–909 (2003)
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Isenbarger D, Long GW et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science244, 1078–1081 (1989).
   PubMed Web of Science ®Google Scholar
• Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol.6, 21–32 (2006).
   PubMed Web of Science ®Google Scholar
• Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol.206, 3803–3808 (2003).
   PubMed Web of Science ®Google Scholar
• Dame JB, Williams JL, McCutchan TF et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science225(4662), 593–599 (1984).
   PubMed Web of Science ®Google Scholar
• Burkot TR, Da ZW, Geysen HM, Wirtz RA, Saul A. Fine specificities of monoclonal antibodies against the Plasmodium falciparum circumsporozoite protein: recognition of both repetitive and non-repetitive regions. Parasite Immunol.13, 161–170 (1991).
   PubMed Web of Science ®Google Scholar
• Herrington DA, Clyde DF, Losonsky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature328, 257–259 (1987).
   PubMed Web of Science ®Google Scholar
• Ballou WR, Hoffman SL, Sherwood JA et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet1(8545), 1277–1281 (1987).
   PubMed Web of Science ®Google Scholar
• Sherwood JA, Oster CN, Adoyo-Adoyo M et al. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure. Trans. R. Soc. Trop. Med. Hyg.85, 336–340 (1991).
   PubMed Web of Science ®Google Scholar
• Sherwood JA, Copeland RS, Taylor KA et al. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine14(8), 817–827 (1996).
   PubMed Web of Science ®Google Scholar
• Brown AE, Singharaj P, Webster HK et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine12, 102–108 (1994).
   PubMed Web of Science ®Google Scholar
• Vreden SGS, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen JH. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am. J. Trop. Med. Hyg.45, 533–538 (1991).
   PubMed Web of Science ®Google Scholar
• Heppner DG Jr, Kester KE, Ockenhouse KF et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine23, 2243–2250 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein/ HBsAg subunit vaccine. J. Infect. Dis.171, 1576–1585 (1995).
   PubMed Web of Science ®Google Scholar
• Garcon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines2(2), 231–238 (2003).
   PubMedGoogle Scholar
• Ballou WR, Kester KE, Heppner DG. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria. Chem. Immunol.80, 253–261 (2002).
   PubMedGoogle Scholar
• Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein malaria vaccine against Plasmodium falciparum. N. Engl. J. Med.336, 86–91 (1997).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis.178, 1139–1144 (1998).
   PubMed Web of Science ®Google Scholar
• Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J. Immunol.171(12), 6961–6967 (2003).
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis.183(4), 640–647 (2001).
   PubMed Web of Science ®Google Scholar
• Doherty JF, Pinder M, Tornieporth N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SBAS2, in semi-immune adults in The Gambia. Am. J. Trop. Med. Hyg.61, 865–868 (1999).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Heppner DG Jr, Mason CJ et al. Phase I safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am. J. Trop. Med. Hyg.75, 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet358, 1927–1934 (2001).
   PubMed Web of Science ®Google Scholar
• Alloueche A, Milligan P, Conway DJ et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am. J. Trop. Med. Hyg.68, 97–101(2003).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine4(23), 4148–4157 (2005).
   Google Scholar
• Alonso P, Sacarlal J, Aponte J et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364, 1411–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized controlled trial. Lancet366, 2012–2018 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine24(42-43), 6483–6492 (2006).
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Walther M, Vuola JM et al. A clinical trial of prime-boost immunization with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine5(24), 2850–2859 (2006).
   Google Scholar